Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material

Chinese Food and Drug Administration Approves Gabexate Mesylate as
Pharmaceutical Raw Material

NANTONG CITY, China, Oct. 8 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma,
Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma") (the "Company") is pleased
to announce that the Company received a certificate for the use of Gabexate
mesylate as a pharmaceutical raw material (Certificate #2009S01805) from the
Chinese State Food and Drug Administration ("SFDA").
Gabexate Mesylate is a serine proteinase inhibitor used therapeutically in
the treatment of pancreatitis, disseminated intravascular coagulation (DIC),
and as a regional anticoagulant for hemodialysis. The drug inhibits the
hydrolytic effects of thrombin, plasmin, and kallikrein, but not of
chymotrypsin and aprotinin.
The Company is now awaiting GMP certification to manufacture Gabexate
mesylate.

About Sinobiopharma
Sinobiopharma, Inc. is a fully integrated and highly innovative specialty
biopharmaceutical company engaged in the research and development, manufacture
and marketing of biopharmaceutical products in China, the world's fastest
growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical
Co., Ltd. in China, the Company's current therapeutic focus is on
anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding
Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such
forward looking statements are within the meaning of Section 27A of the
Securities Act of 1933, as amended, and section 21E of the United States
Securities and Exchange Act of 1934, as amended, and are intended to be
covered by the safe harbor created by such sections. Where Sinobiopharma, Inc.
expresses or implies an expectation or belief as to future events or results,
such expectation or belief is believed to have a reasonable basis. However,
forward-looking statements are subject to risks, uncertainties and other
factors, which could cause actual results to differ materially from future
results expressed, projected or implied by such forward-looking statements.
Sinobiopharma, Inc. does not undertake any obligation to update any forward
looking statement, except as required under applicable law.

SOURCE Sinobiopharma, Inc.